InvAscent Exits Symbiotec Pharmalab Via IPO And Pre-IPO Sales

InvAscent advised Rosewood Investment on a partial exit from Symbiotec Pharmalab via pre-IPO share sales, followed by the IPO. The partnership began with an INR 3.44 billion investment in December 2018; the fund retained a meaningful stake post-listing. Symbiotec manufactures corticosteroid, steroid-hormone APIs; it has expanded into CDMO services and complex injectables during the holding period.